GlassScriptPhysician profile
Kathy C Lynn
NPI 1932145208
$9,905.44
in general payments reported to CMS, 2019-2025
46 companies · $988 in 2025
The $988 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $875 · 2021: $959 · 2022: $1,160 · 2023: $2,423 · 2024: $1,803 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,927 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,926.92 |
| Education | $286.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,776.16 | 2019-2025 | |
| Amgen INC. | $1,666.05 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $837.04 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $621.05 | 2019-2025 | Tremfya, Symtuza, Stelara |
| Genzyme Corporation | $574.24 | 2019-2025 | |
| Octapharma USA, INC. | $328.44 | 2020-2024 | Octagam Immune Globulin (Human) |
| Novartis Pharmaceuticals Corporation | $302.48 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $263.00 | 2021-2024 | Lupkynis |
| Takeda Pharmaceuticals U.S.A., INC. | $254.21 | 2020-2024 | Cuvitru |
| Pfizer INC. | $245.34 | 2019-2025 | |
| Horizon Therapeutics Plc | $243.51 | 2019-2023 | Krystexxa |
| Sobi, INC | $224.38 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $196.42 | 2020-2025 | Acthar |
| Merck Sharp & Dohme LLC | $183.26 | 2019-2023 | Zerbaxa, Recarbrio, Dificid |
| Organon LLC | $180.00 | 2023-2025 | Hadlima, Renflexis |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $162.44 | 2023-2025 | Idacio, Tyenne |
| Melinta Therapeutics, LLC | $157.37 | 2019-2021 | |
| Sandoz INC. | $134.11 | 2023-2025 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $127.98 | 2019-2023 | |
| Lilly USA, LLC | $123.91 | 2019-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.03 | 2019-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $112.43 | 2020-2024 | Orencia |
| Medtronic USA, INC. | $102.70 | 2020 | |
| Csl Behring | $100.10 | 2019-2023 | Hizentra |
| Genentech USA, INC. | $94.24 | 2019-2020 | |
| Kerecis Limited | $77.29 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $75.23 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $64.69 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $62.56 | 2019 | |
| Viiv Healthcare Company | $56.68 | 2021-2023 | Rukobia |
| Organogenesis INC. | $49.70 | 2023 | Puraply |
| Scilex Pharmaceuticals INC. | $46.22 | 2024 | |
| Glaxosmithkline, LLC. | $38.45 | 2021-2024 | Benlysta |
| Astellas Pharma US INC | $38.14 | 2019-2020 | |
| Shire North American Group INC | $34.16 | 2019 | |
| Theratechnologies INC. | $31.33 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $30.07 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.29 | 2022 | |
| Invivyd INC | $26.16 | 2025 | Pemgarda |
| Paratek Pharmaceuticals, INC. | $20.58 | 2020 | |
| Mayne Pharma Commercial LLC | $19.98 | 2021 | |
| Celltrion USA INC. | $18.97 | 2023 | Yuflyma |
| Abbott Laboratories | $18.70 | 2022 | |
| Bioventus LLC | $16.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2024 | Saphnelo |
| Tetraphase Pharmaceuticals, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Lynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.